APO Research
Talk to an analyst

APO RESEARCH · REPORT

Split Influenza Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Split Influenza Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchSplit Influenza Vaccine Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Split Influenza Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Split Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Split Influenza Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Split Influenza Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Split Influenza Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Split Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Split Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Split Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Split Influenza Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Split Influenza Vaccine market include CSL Seqirus, Seqirus, Inc., straZeneca, Dalian Yali Peak, GSK and Sanofi Pasteur, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Split Influenza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Split Influenza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Split Influenza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Split Influenza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Split Influenza Vaccine Segment by Company

CSL Seqirus

Seqirus, Inc.

straZeneca

Dalian Yali Peak

GSK

Sanofi Pasteur

Split Influenza Vaccine Segment by Type

Aldult

Child

Split Influenza Vaccine Segment by Application

Hospital

Clinic

Split Influenza Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Split Influenza Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Split Influenza Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Split Influenza Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Split Influenza Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Split Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Split Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Split Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Split Influenza Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Split Influenza Vaccine industry.

Chapter 3: Detailed analysis of Split Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Split Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Split Influenza Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Split Influenza Vaccine Industry Trends Table 2. Split Influenza Vaccine Industry Drivers Table 3. Split Influenza Vaccine Industry Opportunities and Challenges Table 4. Split Influenza Vaccine Industry Restraints Table 5. Global Split Influenza Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Split Influenza Vaccine Revenue Share by Company (2021-2026) Table 7. Global Split Influenza Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Split Influenza Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Split Influenza Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Split Influenza Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Split Influenza Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Split Influenza Vaccine Company, Product Type & Application Table 13. Global Split Influenza Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Split Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Aldult Table 18. Significant Companies of Child Table 19. Global Split Influenza Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Split Influenza Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Split Influenza Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Split Influenza Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Split Influenza Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Split Influenza Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Split Influenza Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Split Influenza Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Split Influenza Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Split Influenza Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Split Influenza Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Split Influenza Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Split Influenza Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Split Influenza Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Split Influenza Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Split Influenza Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Split Influenza Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Split Influenza Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Split Influenza Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Split Influenza Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Split Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Split Influenza Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Split Influenza Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Split Influenza Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Split Influenza Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Split Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Split Influenza Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Split Influenza Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Split Influenza Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Split Influenza Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Split Influenza Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Split Influenza Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Split Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Split Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Split Influenza Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Split Influenza Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Split Influenza Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Split Influenza Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Split Influenza Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Split Influenza Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Split Influenza Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Split Influenza Vaccine Sales Value Market Share by Country (2027-2032) Table 63. CSL Seqirus Company Information Table 64. CSL Seqirus Business Overview Table 65. CSL Seqirus Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. CSL Seqirus Split Influenza Vaccine Product Portfolio Table 67. CSL Seqirus Recent Development Table 68. Seqirus, Inc. Company Information Table 69. Seqirus, Inc. Business Overview Table 70. Seqirus, Inc. Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Seqirus, Inc. Split Influenza Vaccine Product Portfolio Table 72. Seqirus, Inc. Recent Development Table 73. straZeneca Company Information Table 74. straZeneca Business Overview Table 75. straZeneca Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. straZeneca Split Influenza Vaccine Product Portfolio Table 77. straZeneca Recent Development Table 78. Dalian Yali Peak Company Information Table 79. Dalian Yali Peak Business Overview Table 80. Dalian Yali Peak Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Dalian Yali Peak Split Influenza Vaccine Product Portfolio Table 82. Dalian Yali Peak Recent Development Table 83. GSK Company Information Table 84. GSK Business Overview Table 85. GSK Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. GSK Split Influenza Vaccine Product Portfolio Table 87. GSK Recent Development Table 88. Sanofi Pasteur Company Information Table 89. Sanofi Pasteur Business Overview Table 90. Sanofi Pasteur Split Influenza Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Sanofi Pasteur Split Influenza Vaccine Product Portfolio Table 92. Sanofi Pasteur Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Split Influenza Vaccine Distributors List Table 96. Split Influenza Vaccine Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Split Influenza Vaccine Product Image Figure 2. Global Split Influenza Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Split Influenza Vaccine Sales (2021-2032) & (k units) Figure 5. Global Split Influenza Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Split Influenza Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Aldult Image Figure 10. Child Image Figure 11. Global Split Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Split Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Split Influenza Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Split Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Split Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Split Influenza Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Split Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Split Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Split Influenza Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Split Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Split Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Split Influenza Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Split Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Split Influenza Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Split Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Split Influenza Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Split Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Split Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Split Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Split Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Split Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Split Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Split Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Split Influenza Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Split Influenza Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Aldult
  • Child
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL Seqirus
  • Seqirus, Inc.
  • straZeneca
  • Dalian Yali Peak
  • GSK
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Split Influenza Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Split Influenza Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Split Influenza Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Split Influenza Vaccine Market Dynamics
  1. 2.1 Split Influenza Vaccine Industry Trends
  2. 2.2 Split Influenza Vaccine Industry Drivers
  3. 2.3 Split Influenza Vaccine Industry Opportunities and Challenges
  4. 2.4 Split Influenza Vaccine Industry Restraints
3 Split Influenza Vaccine Market by Company
  1. 3.1 Global Split Influenza Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Split Influenza Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Split Influenza Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Split Influenza Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Split Influenza Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Split Influenza Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Split Influenza Vaccine Company Product Type and Application
  8. 3.8 Global Split Influenza Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Split Influenza Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Split Influenza Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Split Influenza Vaccine Market by Type
  1. 4.1 Split Influenza Vaccine Type Introduction
  2. 4.1.1 Aldult
  3. 4.1.2 Child
  4. 4.2 Global Split Influenza Vaccine Sales Volume by Type
  5. 4.2.1 Global Split Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Split Influenza Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Split Influenza Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Split Influenza Vaccine Sales Value by Type
  9. 4.3.1 Global Split Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Split Influenza Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Split Influenza Vaccine Sales Value Share by Type (2021-2032)
5 Split Influenza Vaccine Market by Application
  1. 5.1 Split Influenza Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Split Influenza Vaccine Sales Volume by Application
  5. 5.2.1 Global Split Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Split Influenza Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Split Influenza Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Split Influenza Vaccine Sales Value by Application
  9. 5.3.1 Global Split Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Split Influenza Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Split Influenza Vaccine Sales Value Share by Application (2021-2032)
6 Split Influenza Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Split Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Split Influenza Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Split Influenza Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Split Influenza Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Split Influenza Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Split Influenza Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Split Influenza Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Split Influenza Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Split Influenza Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Split Influenza Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Split Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Split Influenza Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Split Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Split Influenza Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Split Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Split Influenza Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Split Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Split Influenza Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Split Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
7 Split Influenza Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Split Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Split Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Split Influenza Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Split Influenza Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Split Influenza Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Split Influenza Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Split Influenza Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Split Influenza Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Split Influenza Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Split Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Split Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Seqirus
  2. 8.1.1 CSL Seqirus Company Information
  3. 8.1.2 CSL Seqirus Business Overview
  4. 8.1.3 CSL Seqirus Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Seqirus Split Influenza Vaccine Product Portfolio
  6. 8.1.5 CSL Seqirus Recent Developments
  7. 8.2 Seqirus, Inc.
  8. 8.2.1 Seqirus, Inc. Company Information
  9. 8.2.2 Seqirus, Inc. Business Overview
  10. 8.2.3 Seqirus, Inc. Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Seqirus, Inc. Split Influenza Vaccine Product Portfolio
  12. 8.2.5 Seqirus, Inc. Recent Developments
  13. 8.3 straZeneca
  14. 8.3.1 straZeneca Company Information
  15. 8.3.2 straZeneca Business Overview
  16. 8.3.3 straZeneca Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 straZeneca Split Influenza Vaccine Product Portfolio
  18. 8.3.5 straZeneca Recent Developments
  19. 8.4 Dalian Yali Peak
  20. 8.4.1 Dalian Yali Peak Company Information
  21. 8.4.2 Dalian Yali Peak Business Overview
  22. 8.4.3 Dalian Yali Peak Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dalian Yali Peak Split Influenza Vaccine Product Portfolio
  24. 8.4.5 Dalian Yali Peak Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GSK Split Influenza Vaccine Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Split Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Split Influenza Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Split Influenza Vaccine Value Chain Analysis
  2. 9.1.1 Split Influenza Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Split Influenza Vaccine Sales Mode & Process
  6. 9.2 Split Influenza Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Split Influenza Vaccine Distributors
  9. 9.2.3 Split Influenza Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst